Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section

• Status: Completed
• Trial end date: 2002-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries.

With this trial, we sought to determine the effectiveness of oral misoprostol as an uterotonic drug in comparison with intravenous oxytocin, in patients with a low risk of PPH undergoing non-scheduled Cesarean section.

We therefore compared the intra- and postoperative blood loss, as well as drug related side effects in patients, treated by the same surgical and anesthesiological team in one institution.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Basel Women’s University Hospital; University Hospital, Basel, Switzerland
• Treatments: Misoprostol; Oxytocin

Criteria

Inclusion Criteria:

• Non-scheduled primary or secondary Cesarean section (CS) after the 37th week of gestation

Exclusion Criteria:

• Emergency CS

• Fetal distress

• Fetal malformations

• Preeclampsia and HELLP (Hemolysis-Elevated Liver enzymes-Low Platelet count syndrome)

• Hypersensitivity to prostaglandins

• Coagulopathy

• Severe systemic disorders

• An American Society of Anesthesiologists (ASA) physical status >/= 3

• Severe asthma

• Prior myomectomy

• Maternal fever (> 38.5 °C)